

This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail.



## Consolidated Financial Results for the Nine Months Ended December 31, 2025 <under Japanese GAAP>

February 13, 2026

Company name: **MatsukiyoCocokara & Co.**  
 Listing: Tokyo Stock Exchange  
 Securities code: 3088  
 URL: <https://www.matsukiyococokara.com/>  
 Representative: Kiyoo Matsumoto, President and Representative Director  
 Inquiries: Hiroshi Nishida, Executive Officer and General Manager of Financial Strategies  
 Office, Group Management  
 TEL: +81-3-6845-0005  
 Scheduled date to commence dividend payments: –  
 Preparation of supplementary material on financial results: Yes  
 Holding of financial results presentation meeting: None

(Amounts less than one million yen are rounded down)

### 1. Consolidated financial results for the nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025)

#### (1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		EBITDA		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended										
December 31, 2025	839,340	4.7	81,644	4.0	64,247	4.2	67,807	4.5	42,589	3.3
December 31, 2024	801,520	4.0	78,487	5.3	61,654	4.9	64,918	4.0	41,219	(2.5)

Note: Comprehensive income  
 Nine months ended December 31, 2025 ¥44,377 million [8.2%]  
 Nine months ended December 31, 2024 ¥41,002 million [4.7%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2025	106.79	106.76
December 31, 2024	100.51	100.48

Note: EBITDA = Operating profit + Depreciation and Amortization of goodwill

#### (2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
December 31, 2025	736,194	530,384	71.9	1,330.62
March 31, 2025	712,780	521,499	73.1	1,290.38

Reference: Equity  
 As of December 31, 2025 ¥529,486 million  
 As of March 31, 2025 ¥520,754 million

## 2. Cash dividends

	Annual cash dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	–	21.00	–	23.00	44.00
Fiscal year ending March 31, 2026	–	24.00	–		
Fiscal year ending March 31, 2026 (forecast)				24.00	48.00

Note: Revisions to dividends forecasts most recently announced: None

## 3. Consolidated earnings forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		EBITDA		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	1,100,000	3.6	108,500	3.6	85,500	4.2	89,500	3.7	56,500	3.3	141.67

Note: Revisions to earnings forecasts most recently announced: None

**\* Notes**

(1) Significant changes in the scope of consolidation during the nine months ended December 31, 2025: Yes

Newly included: 2 companies (MATSUMOTO KIYOSHI (HK) CO., LIMITED and Shinseidoyakkyoku co. ltd.)

Excluded: – companies (Company names)

(2) Adoption of special accounting treatments for preparing quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

a. Changes in accounting policies due to revisions to accounting standards and other regulations: None

b. Changes in accounting policies due to other reasons: None

c. Changes in accounting estimates: None

d. Restatement: None

(4) Number of issued shares (common shares)

a. Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2025	410,275,830 shares
As of March 31, 2025	415,675,630 shares

b. Number of treasury shares at the end of the period

As of December 31, 2025	12,349,442 shares
As of March 31, 2025	12,107,808 shares

c. Average number of shares during the period

Nine months ended December 31, 2025	398,802,012 shares
Nine months ended December 31, 2024	410,097,370 shares

Note: The number of treasury shares at the end of each period includes shares of the Company held by the BIP (Board Incentive Plan) Trust Account and the Share Grant ESOP (Employee Stock Ownership Plan) Trust Account (662,640 shares as of December 31, 2025 and 392,896 shares as of March 31, 2025). The shares of the Company held by the BIP Trust Account and the Share Grant ESOP Trust Account are included in the number of treasury shares deducted in the calculation of average number of shares during each period.

\* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: No

\* Proper use of earnings forecasts, and other special matters  
(Caution regarding forward-looking statements and others)

The earnings forecasts shown above are prepared based on the information available to us as of the date of this release. Actual results may be different from these forecasts due to various factors. For the assumptions related matters concerning the earnings forecasts, please refer to page 4.

## 1. Qualitative Information

### (1) Details of operating results

During the nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025), the Japanese economy picked up moderately due to improving employment and income environments. However, factors including increased geopolitical risks and fluctuations in the financial and capital markets mean that unpredictability of future outlook persists.

The drugstore industry in which the Company operates also continues to face a challenging business environment, with new store openings by competitors across industries and business categories. This is also due to entrance into new areas aimed at commercial area expansion, expansion of scale through M&A, competition with different industries that are becoming homogenous, as well as the narrowing of the commercial area of individual stores caused by all of these factors.

In such an environment, we are promoting the following three key strategies in line with our basic approach of “Co-creating and sharing value.” These strategies have been formulated to achieve the Group management targets for the fiscal year ending March 31, 2031.

#### (1) Differentiation strategy: Strengthen our unique platform business

Aiming to continue being the company customers choose, we will continue to deliver new forms of value that we alone can provide in our business domain comprising the health and beauty fields. To that end, we are committed to enhancing customer convenience through seamless coordination between our drugstore and pharmacy businesses and driving the expansion of our unique domains including our own unique B-to-B business. In striving to achieve these aims, we will leverage our strengths including the attractive merchandise, services, value, and experiences we offer; our store network concentrated mainly in major metropolitan regions; and the closed (private, confidential, or undisclosed) information accumulated from numerous customer contact points.

#### (2) Investment strategy: Invest in business infrastructure for co-creating value

We are aiming to earn sustained profits by actively investing in the infrastructure that underpins our platform. In specific terms, we are undertaking proactive investment in systems to improve customer convenience and operational efficiency through digital technology, and to expand our business domains. We boosted store openings in our priority areas mainly in major metropolitan regions. We are also seeking to increase our operational scale by promoting M&A activities, and in order to facilitate participation in the Group and advance our alliance concept, we established a new intermediate holding company, And Company Co., Ltd., on August 1, 2025, and made Shinseidoyakkyoku co. ltd., which operates dispensing pharmacies and drugstores in the northern Kyushu area, a subsidiary of the new company, thereby promoting the opening of dispensing pharmacies next to drugstores. As a result, as of December 31, 2025, the number of stores in Japan for the Group totaled 3,604 (including 1,103 pharmacies). We are also expanding our overseas operations by moving into new markets primarily in the ASEAN countries, including the launch of our operations in Malaysia. At the same time, we are investing in human capital by developing a workplace environment that is easy for employees to work in and offers job satisfaction and motivation. We are also continually seeking to nurture professional, global human resources and increase employee engagement.

#### (3) Social contribution and returning profit to society: Practice sustainable management that contributes to the enhancement of corporate value

Aiming to practice sustainable management that helps to achieve our Management Philosophy and Group Vision, and to enhance corporate value, we are undertaking the following initiatives: make stable returns to stakeholders; enhance corporate governance; take action for the benefit of the environment and society (respond to climate change and support for community healthcare); and respond to the demands of the capital markets (practice management conscious of the cost of capital and consider our optimal capital structure).

As a result, key operating results during the nine months ended December 31, 2025 were as follows.

	Nine months ended December 31, 2024 (Millions of yen)	Nine months ended December 31, 2025 (Millions of yen)	Change (Millions of yen)	Change (%)
Net sales	801,520	839,340	37,819	4.7
Operating profit	61,654	64,247	2,593	4.2
Ordinary profit	64,918	67,807	2,889	4.5
Profit attributable to owners of parent	41,219	42,589	1,369	3.3

#### Overview of operating results by segment

##### <Matsumotokiyoshi Group business>

In the Matsumotokiyoshi Group business, the Matsumotokiyoshi Group is pursuing a differentiation strategy by leveraging 166.52 million customer contact points. This includes promoting measures to integrate its physical stores, apps, and e-commerce; enhancing customer convenience through seamless coordination between its drugstore and pharmacy businesses; and improving operational efficiency through digital technology.

As for the private brand product lineup, the Matsumotokiyoshi Group worked to enhance brand recognition and value in celebration of the 10th anniversary of the “matsukiyo” brand by hosting its first experiential pop-up store, “matsukiyo Beauty School,” and launching an industry-first special collaboration with a popular cosmetics brand. In addition, the Matsumotokiyoshi Group continued to promote the development of high value-added products that meet customer needs by launching “BEAUSTER,” a new supplement series from matsukiyo LAB specializing in ingredient-focused beauty care, and by expanding the lineup of existing brands such as the “Immune Care Series” and “MQURE.”

In addition, the Matsumotokiyoshi Group is advancing its investment strategy: boosting store openings in its priority areas mainly in metropolitan regions, promoting the opening of dispensing pharmacies next to drugstores, and expanding its overseas operations, including moving into new markets primarily in the ASEAN countries. To further promote store development that symbolizes the Group’s new initiatives, the Matsumotokiyoshi Group fully renovated its Ginza 5th store and reopened it as its fifth flagship location, “GINZA FLAG.” The store features a lineup of products that are first-of-their-kind in Japan and in the drugstore industry, and offers an advanced customer experience through immersive digital signage. Through these efforts, the Matsumotokiyoshi Group aims to further enhance its brand image and differentiate itself from competitors. As of December 31, 2025, the number of stores in Japan for the Matsumotokiyoshi Group business totaled 1,959 (including 476 dispensing pharmacies), and we expanded the member store network of the Community Pharmacy Support Program, which is a pharmacy management support service, to include 312 stores. We opened a new store in Malaysia, and as a result, we now operate 98 stores overseas in total, with 37 stores in Thailand, 24 stores in Taiwan, 18 stores in Vietnam, 17 stores in Hong Kong, one store in Guam, and one store in Malaysia.

By effectively capturing the increased flow of people in urban areas, downtown, and commercial facilities, as well as the demand trends of overseas tourists visiting Japan, the Matsumotokiyoshi Group business showed strong sales, mainly in cosmetics.

##### <Cocokarafine Group business>

In the Cocokarafine Group business, the Cocokarafine Group is engaging in efforts similar to those taken on by the Matsumotokiyoshi Group business under the key domestic strategies, including differentiation and investment strategies. The Cocokarafine Group is promoting building a loyal customer base by implementing efficient and effective app-based sales promotion measures. In addition, based on the plan for the current fiscal year, it is taking a scrap-and-build approach aimed at reallocating human capital and optimizing management resources to further improve profitability. As of December 31, 2025, the number of stores in Japan for the Cocokarafine Group business totaled 1,533 (including 534 dispensing pharmacies).

##### <And Company business>

The And Company business was newly added as a reportable segment in the third quarter ended December 31, 2025 following the acquisition of Shinseidoyakkyoku co. ltd., which operates dispensing pharmacies and drugstores mainly in the northern Kyushu area, as a subsidiary on October 1, 2025.

By combining the company's strengths with the know-how and resources of the Group, we aim to expand our share in dominant areas and enhance customer convenience. We are currently advancing specific initiatives and examinations to generate synergies, including product procurement and systems integration. As of December 31, 2025, the number of stores in Japan for And Company business totaled 112 (including 93 pharmacies).

[Numbers of store openings and closures in Japan]

Numbers of store openings and closures in Japan were as follows.

	(Number of stores)				
	Number of stores as of March 31, 2025	Acquired as a subsidiary, etc.	Openings	Closings	Number of stores as of December 31, 2025
Matsumotokiyoshi Group business	1,938	—	46	25	1,959
Cocokarafine Group business	1,561	—	15	43	1,533
And Company business	—	112	—	—	112
Total	3,499	112	61	68	3,604

#### <Management support business>

In the management support business, the scope of the Company's business activities has been expanded to include management support business, which refers to the purchase of products handled by the Company's group companies, business management and control of the Company's group companies, contracted back-office services, dividend income from the Company's group companies, supply of products to companies other than the Company's group companies, construction operations, advertising, etc.

As a result, operating results by segment were as follows:

		Nine months ended December 31, 2024 (Millions of yen)	Nine months ended December 31, 2025 (Millions of yen)	Change (Millions of yen)	Change (%)
Matsumotokiyoshi Group business	Net sales	501,880	534,764	32,884	6.6
	Segment profit	42,450	44,735	2,284	5.4
Cocokarafine Group business	Net sales	296,842	295,613	(1,228)	(0.4)
	Segment profit	18,575	17,918	(656)	(3.5)
And Company business	Net sales	—	6,622	6,622	—
	Segment profit	—	133	133	—
Management support business	Net sales	504,294	524,393	20,098	4.0
	Segment profit	20,589	18,238	(2,351)	(11.4)
Adjustments	Net sales	(501,496)	(522,054)	(20,557)	—
	Segment profit	(19,961)	(16,778)	3,183	—
Total	Net sales	801,520	839,340	37,819	4.7
	Segment profit	61,654	64,247	2,593	4.2

**(2) Details of financial position**

Total assets as of the end of the third quarter ended December 31, 2025 increased by ¥23,413 million from the end of the previous fiscal year to ¥736,194 million. This was mainly due to increases of ¥16,407 million in merchandise, ¥11,576 million in accounts receivable – trade, and ¥4,427 million in other under property, plant and equipment, despite a decrease of ¥12,579 million in cash and deposits.

Total liabilities increased by ¥14,528 million to ¥205,809 million. This was mainly due to increases of ¥18,224 million in accounts payable – trade and ¥4,763 million in other under current liabilities, despite a decrease of ¥8,410 million in income taxes payable.

Net assets increased by ¥8,885 million to ¥530,384 million. This was mainly due to an increase of ¥22,381 million in retained earnings, despite a decrease of ¥12,133 million in capital surplus.

**(3) Consolidated earnings forecasts and other forward-looking statements**

No changes have been made to the consolidated earnings forecasts for the fiscal year ending March 31, 2026 that were announced on May 9, 2025.

**2. Quarterly Consolidated Financial Statements and Significant Notes Thereto****(1) Quarterly consolidated balance sheet**

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
<b>Assets</b>		
Current assets		
Cash and deposits	111,750	99,170
Accounts receivable - trade	64,469	76,046
Merchandise	144,168	160,575
Supplies	1,050	1,029
Other	42,947	46,563
Allowance for doubtful accounts	(70)	(230)
Total current assets	364,316	383,154
Non-current assets		
Property, plant and equipment		
Land	50,300	50,539
Other	60,578	65,005
Total property, plant and equipment	110,878	115,544
Intangible assets		
Goodwill	99,259	100,516
Other	28,777	30,137
Total intangible assets	128,036	130,654
Investments and other assets		
Investment securities	27,786	28,573
Leasehold and guarantee deposits	61,200	62,104
Other	20,700	16,984
Allowance for doubtful accounts	(139)	(821)
Total investments and other assets	109,548	106,840
Total non-current assets	348,463	353,039
Total assets	712,780	736,194

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
<b>Liabilities</b>		
Current liabilities		
Accounts payable - trade	108,176	126,401
Income taxes payable	16,611	8,200
Short-term borrowings	1,187	1,510
Provision for bonuses	5,754	2,924
Provision for point card certificates	228	347
Contract liabilities	3,575	4,672
Asset retirement obligations	15	19
Other	27,091	31,854
<b>Total current liabilities</b>	<b>162,640</b>	<b>175,931</b>
Non-current liabilities		
Provision for directors' retirement benefits	—	337
Provision for loss on guarantees	146	97
Provision for share awards	308	363
Provision for share awards for directors (and other officers)	39	39
Retirement benefit liability	31	374
Asset retirement obligations	14,472	15,192
Other	13,641	13,471
<b>Total non-current liabilities</b>	<b>28,640</b>	<b>29,877</b>
<b>Total liabilities</b>	<b>191,280</b>	<b>205,809</b>
Net assets		
Shareholders' equity		
Share capital	22,051	22,051
Capital surplus	178,879	166,745
Retained earnings	338,939	361,321
Treasury shares	(24,946)	(27,997)
<b>Total shareholders' equity</b>	<b>514,924</b>	<b>522,120</b>
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5,927	7,206
Foreign currency translation adjustment	(96)	159
<b>Total accumulated other comprehensive income</b>	<b>5,830</b>	<b>7,366</b>
Share acquisition rights	43	43
Non-controlling interests	701	854
<b>Total net assets</b>	<b>521,499</b>	<b>530,384</b>
<b>Total liabilities and net assets</b>	<b>712,780</b>	<b>736,194</b>

**(2) Quarterly consolidated statement of income and consolidated statement of comprehensive income****Quarterly consolidated statement of income**

(Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Net sales	801,520	839,340
Cost of sales	522,962	545,504
Gross profit	278,558	293,835
Selling, general and administrative expenses		
Provision for point card certificates	105	118
Salaries and allowances	80,289	85,380
Provision for bonuses	2,918	2,878
Retirement benefit expenses	1,685	1,795
Rent expenses on land and buildings	55,631	59,291
Other	76,274	80,122
Total selling, general and administrative expenses	216,904	229,587
Operating profit	61,654	64,247
Non-operating income		
Interest income	105	207
Dividend income	367	388
Gain on receipt of donated non-current assets	275	345
Order processing commission	1,362	1,532
Research fee income	449	485
Other	847	737
Total non-operating income	3,407	3,696
Non-operating expenses		
Interest expenses	48	55
Loss on investments in investment partnerships	50	50
Cash over and short	3	1
Other	41	29
Total non-operating expenses	142	136
Ordinary profit	64,918	67,807
Extraordinary income		
Gain on sale of non-current assets	300	19
Gain on sale of investment securities	92	0
Total extraordinary income	393	19
Extraordinary losses		
Loss on sale of non-current assets	64	24
Loss on retirement of non-current assets	196	274
Loss on sale of investment securities	89	—
Loss on store closings	91	190
Impairment losses	203	135
Loss on disaster	※ 58	—
Compensation for damage	—	65
Total extraordinary losses	704	691
Profit before income taxes	64,607	67,135
Income taxes - current	21,489	22,284
Income taxes - deferred	1,646	2,009
Total income taxes	23,135	24,293
Profit	41,472	42,841
Profit attributable to non-controlling interests	252	252
Profit attributable to owners of parent	41,219	42,589

**Quarterly consolidated statement of comprehensive income**

(Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Profit	41,472	42,841
Other comprehensive income		
Valuation difference on available-for-sale securities	(482)	1,278
Foreign currency translation adjustment	12	256
Total other comprehensive income	(469)	1,535
Comprehensive income	41,002	44,377
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	40,749	44,124
Comprehensive income attributable to non-controlling interests	252	252

**(3) Notes to quarterly consolidated financial statements*****(Notes on going concern assumption)***

Not applicable.

***(Changes in scope of consolidation or equity method)***

During the three months ended June 30, 2025, MATSUMOTO KIYOSHI (HK) CO., LIMITED, which had previously been a non-consolidated subsidiary, was included in the scope of consolidation due to its increased materiality.

During the third quarter ended December 31, 2025, Shinseidoyakkyoku co. ltd. was also included in the scope of consolidation due to the acquisition of its all shares, which resulted in its becoming a subsidiary.

***(Notes when there are significant changes in amounts of shareholders' equity)******(Acquisition of own shares)***

Pursuant to the resolution passed at the meeting of the Board of Directors held on May 9, 2025, the Company acquired 5,399,800 of its own shares. As a result of this acquisition, treasury shares increased by ¥14,471 million during the nine months ended December 31, 2025.

***(Cancellation of treasury shares)***

Pursuant to the resolution passed at the meeting of the Board of Directors held on May 9, 2025, the Company cancelled 5,399,800 of its treasury shares effective June 10, 2025. As a result, capital surplus and treasury shares each decreased by ¥12,160 million during the nine months ended December 31, 2025.

***(Quarterly consolidated balance sheet)*****Overdraft agreements**

The Company has concluded overdraft agreements with 13 counterparty financial institutions for the fiscal year ended March 31, 2025 and with 13 counterparty financial institutions as of December 31, 2025, for the efficient procurement of funds. The balance of unexecuted borrowings as of December 31, 2025 based on these agreements is as follows.

	(Millions of yen)	
	As of March 31, 2025	As of December 31, 2025
Total amount of overdraft agreements	54,500	53,900
Less amounts executed	-	-
Unexecuted balance	54,500	53,900

***(Quarterly consolidated statement of income)*****\* Loss on disaster**

Nine months ended December 31, 2024

Loss on disaster due to torrential rains on the Noto Peninsula in September 2024 was recognized under extraordinary losses.

Nine months ended December 31, 2025

Not applicable.

***(Quarterly consolidated statement of cash flows)***

\* The Company has not prepared a quarterly consolidated statement of cash flows for the nine months ended December 31, 2025. Depreciation (including amortization of intangible assets excluding goodwill) and amortization of good will for the nine months ended December 31, 2024 and the nine months ended December 31, 2025 are as follows.

	(Millions of yen)	
	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Depreciation	11,923	12,378
Amortization of goodwill	4,859	4,963

**(Segment information)**

[Segment information]

I Nine months ended December 31, 2024

## 1. Disclosure of net sales and profit (loss) by reportable segment

(Millions of yen)

	Matsumotokiyoshi Group business	Cocokarafine Group business	And Company business	Management support business	Total	Adjustments (Note 1)	Amounts in the quarterly consolidated statement of income (Note 2)
Net sales							
Sales to external customers	501,676	296,806	—	3,037	801,520	—	801,520
Intersegment sales or transfers	204	35	—	501,257	501,496	(501,496)	—
Total	501,880	296,842	—	504,294	1,303,017	(501,496)	801,520
Segment profit	42,450	18,575	—	20,589	81,615	(19,961)	61,654

Notes: 1. The adjustment of negative ¥19,961 million for segment profit includes negative ¥19,961 million of intersegment transaction elimination.  
2. Segment profit is adjusted with operating profit stated in the quarterly consolidated statement of income.

## 2. Disclosure of impairment loss on non-current assets or goodwill for each reportable segment

*(Significant impairment loss on non-current assets)*

The Group primarily regards stores as a base unit for its minimum cash flow-generating unit, while grouping idle assets according to each property unit. With regard to the asset groups whose operating profit has consistently been negative and asset groups for which the market prices fell considerably, such as land, the Group wrote off their carrying amount to the recoverable amount and recognized the amount of the write-off of ¥203 million as an impairment loss under extraordinary losses.

The breakdown of the impairment loss is ¥60 million for the Matsumotokiyoshi Group business and ¥144 million for the Cocokarafine Group business.

## II Nine months ended December 31, 2025

## 1. Disclosure of net sales and profit (loss) by reportable segment

							(Millions of yen)	
	Matsumotokiyoshi Group business	Cocokarafine Group business	And Company business	Management support business	Total	Adjustments (Note 1)	Amounts in the quarterly consolidated statement of income (Note 2)	
Net sales								
Sales to external customers	534,448	295,577	6,622	2,692	839,340	—	839,340	
Intersegment sales or transfers	316	36	—	521,701	522,054	(522,054)	—	
Total	534,764	295,613	6,622	524,393	1,361,394	(522,054)	839,340	
Segment profit	44,735	17,918	133	18,238	81,026	(16,778)	64,247	

Notes: 1. The adjustment of negative ¥16,778 million for segment profit includes negative ¥16,778 million of intersegment transaction elimination.

2. Segment profit is adjusted with operating profit stated in the quarterly consolidated statement of income.

## 2. Disclosure of impairment loss on non-current assets or goodwill for each reportable segment

*(Significant impairment loss on non-current assets)*

The Group primarily regards stores as a base unit for its minimum cash flow-generating unit, while grouping idle assets according to each property unit. With regard to the asset groups whose operating profit has consistently been negative and asset groups for which the market prices fell considerably, such as land, the Group wrote off their carrying amount to the recoverable amount and recognized the amount of the write-off of ¥135 million as an impairment loss under extraordinary losses.

The breakdown of the impairment loss is ¥37 million for the Matsumotokiyoshi Group business and ¥98 million for the Cocokarafine Group business.

*(Significant changes in the amount of goodwill)*

Goodwill of ¥5,839 million was recognized in the “And Company business” as a result of including Shinseidoyakkyoku co. ltd. in the scope of consolidation during the third quarter ended December 31, 2025. The amount of goodwill has been tentatively calculated, as the allocation of the acquisition cost has not been completed.

## 3. Disclosure of changes, etc. for each reportable segment

Due to Shinseidoyakkyoku co. ltd. becoming a consolidated subsidiary in the third quarter ended December 31, 2025, the Group has defined the business comprising this company and And Company Co., Ltd., a newly established intermediate holding company in the fiscal year ending March 31, 2026, as the “And Company business” and added it as a reportable segment.

Segment information for the nine months ended December 31, 2024 has been restated in accordance with the new segment classification.

**(Business combination)**

## Business combination through acquisition

The Company, at the Board of Directors meeting held on August 13, 2025, resolved to acquire all shares of Shinseidoyakkyoku co. ltd. and make it a subsidiary. A share transfer agreement was executed on the same day, and the acquisition was completed on October 1, 2025.

## (1) Outline of the business combination

## a. Name and business description of the acquiree

Name of the acquiree: Shinseidoyakkyoku co. ltd.

Business description: Drugstore business, dispensing pharmacy business

## b. Primary reasons for conducting the business combination:

To contribute to the creation of healthy communities, mainly in northern Kyushu, Shinseidoyakkyoku operates 119 dispensing pharmacies and drugstores as a group, and strives to extend healthy life expectancies and reduce social security costs. Since its establishment in 1978, Shinseidoyakkyoku has upheld the management philosophy of “helping people lead healthy lives,” and aims to become the best healthcare station in the region by increasing the number of smiles on people’s faces as much as possible.

In order to realize the alliance concept and further expand the scale of business, which were set as medium-term management targets for the fiscal year ending March 31, 2031, the Company has decided to acquire 100% of the shares of Shinseidoyakkyoku and invite it into the Group.

## c. Date of the business combination: October 1, 2025

## d. Legal form of the business combination: Acquisition of shares for cash consideration

## e. Name of company after the business combination: No change

## f. Ratio of voting rights acquired: 100%

## g. Primary grounds for determining the acquiring company: The Company acquired shares in exchange for cash consideration.

## (2) Period during which the acquiree’s financial results are included in the quarterly consolidated financial statements

From October 1, 2025 to December 31, 2025

## (3) Acquisition cost of the acquiree and breakdown by type of consideration

Consideration for acquisition	Cash:	¥11,504 million
Acquisition cost		¥11,504 million

## (4) Description and amount of major acquisition-related expenses

Advisory fees, etc. ¥17 million

## (5) Amount of goodwill incurred, reasons for the goodwill incurred, and the method and period of amortization

## a. Amount of goodwill incurred

¥5,839 million

The amount of goodwill has been tentatively calculated, as the allocation of the acquisition cost had not been completed as of the end of the third quarter ended December 31, 2025.

## b. Reasons for the goodwill incurred

The excess earning power expected to be realized through future business development

## c. Method and period of amortization

Straight-line amortization over 18 years

## (6) Amount of assets accepted and liabilities assumed on the business combination date and their main breakdown

Current assets	¥7,186 million
Non-current assets	¥5,685 million
<hr/> Total assets	<hr/> ¥12,871 million
Current liabilities	¥5,254 million
Non-current liabilities	¥1,952 million
<hr/> Total liabilities	<hr/> ¥7,207 million

**(Revenue recognition)**

Information on disaggregation of revenue from contracts with customers

In information on disaggregation of revenue from contracts with customers, net sales in each reportable segment are disaggregated into revenue from contracts with customers and other income, and revenue from contracts with customers is further disaggregated into net sales from retail sales and other net sales.

Nine months ended December 31, 2024

(Millions of yen)

	Reportable segment				Total
	Matsumotokiyoshi Group business	Cocokarafine Group business	And Company business	Management support business	
Retail					
Medical and pharmaceutical products	152,008	123,658	—	—	275,666
Cosmetics	178,336	90,231	—	—	268,568
General merchandise	93,759	54,303	—	—	148,062
Food	47,514	22,429	—	—	69,944
Other (Note 1)	28,552	5,535	—	2,803	36,891
Revenue from contracts with customers	500,170	296,158	—	2,803	799,133
Other revenue (Note 2)	1,505	648	—	234	2,387
Sales to external customers	501,676	296,806	—	3,037	801,520

Notes: 1. Includes net sales from the wholesale business, net sales from advertising, etc.

2. Includes real estate rental income pursuant to the “Accounting Standard for Lease Transactions” (ASBJ Statement No. 13).

Nine months ended December 31, 2025

(Millions of yen)

	Reportable segment				Total
	Matsumotokiyoshi Group business	Cocokarafine Group business	And Company business	Management support business	
Retail					
Medical and pharmaceutical products	158,839	124,021	4,334	—	287,195
Cosmetics	196,183	91,783	1,029	—	288,996
General merchandise	95,196	51,145	742	—	147,084
Food	51,714	21,348	439	—	73,501
Other (Note 1)	31,066	6,630	59	2,522	40,279
Revenue from contracts with customers	533,001	294,928	6,604	2,522	837,057
Other revenue (Note 2)	1,446	648	17	170	2,282
Sales to external customers	534,448	295,577	6,622	2,692	839,340

Notes: 1. Includes net sales from the wholesale business, net sales from advertising, etc.

2. Includes real estate rental income pursuant to the “Accounting Standard for Lease Transactions” (ASBJ Statement No. 13).

3. Due to the establishment of And Company Co., Ltd. as an intermediate holding company, the business has been defined as the “And Company business” and added as a reportable segment.

***(Significant events after reporting period)***

Not applicable.

### 3. Supplementary Information

#### Net sales and purchases

##### (1) Net sales by operating segment

Net sales by segment for the nine months ended December 31, 2025 are as follows:

Segments	Nine months ended December 31, 2025	
	Amount (Millions of yen)	Changes from the corresponding period of the previous fiscal year (%)
Matsumotokiyoshi Group business	534,448	106.5
Cocokarafine Group business	295,577	99.6
And Company business	6,622	—
Management support business	2,692	88.6
Total	839,340	104.7

Notes: 1. Intersegment transactions are eliminated.

2. Due to the establishment of And Company Co., Ltd. as an intermediate holding company, the business has been defined as the “And Company business” and added as a reportable segment.

##### (2) Net sales by product

Net sales by product for the nine months ended December 31, 2025 are as follows:

Products	Nine months ended December 31, 2025	
	Amount (Millions of yen)	Changes from the corresponding period of the previous fiscal year (%)
Medical and pharmaceutical products	287,195	104.2
Cosmetics	288,996	107.6
General merchandise	147,084	99.3
Food	73,501	105.1
Total	796,778	104.5

Note: Net sales by product do not include sales of the management support business. In addition, the amounts above do not include operating revenue (rent income from tenants and royalty income from franchisees).

##### (3) Purchases by product

Purchases by product for the nine months ended December 31, 2025 are as follows:

Products	Nine months ended December 31, 2025	
	Amount (Millions of yen)	Changes from the corresponding period of the previous fiscal year (%)
Medical and pharmaceutical products	164,685	102.4
Cosmetics	189,537	105.0
General merchandise	103,902	95.2
Food	63,526	103.0
Total	521,652	101.9

Note: Purchases by product do not include purchases of the management support business.